Skip to main content
NCBI home page
Cancer Diagnosis & Prognosis logoLink to Cancer Diagnosis & Prognosis
. 2024 Mar 3;4(2):129–134. doi: 10.21873/cdp.10298

Comparative Expression Analysis of TP53 Tumor Suppressor and MDM2 Oncogene in Colorectal Adenocarcinoma

ATHANASIOS NIOTIS 1, DIMITRIOS DIMITROULIS 1, DESPOINA SPYROPOULOU 2, EVANGELOS TSIAMBAS 3,4, HELEN SARLANIS 3, DIMITRIOS DAVRIS 5, EVANGELOS FALIDAS 5, NIKOLAOS KAVANTZAS 3, DIMITRIOS PESCHOS 6, LOUKAS MANAIOS 7, KONSTANTINOS C KONSTANTINIDIS 8
PMCID: PMC10905287  PMID: 38434910

Abstract

Background/Aim

The tumor protein 53 (TP53) tumor suppressor protein (17p13.1) acts as a significant regulator for the cell cycle normal function. The gene is frequently mutated in colorectal adenocarcinoma (CRC) patients and is associated to poor prognosis and low response rates to chemo-targeted therapy. Our purpose was to correlate TP53 expression with Mouse Double Minute 2 Homolog (MDM2), a proto-oncogene (12q14.3) and a major negative regulator in the TP53-MDM2 auto-regulatory pathway.

Materials and Methods

A total of forty (n=40) colorectal adenocarcinoma (CRC) cases were included in this study. An immunohistochemistry-based assay was implemented by using anti-TP53 and anti-MDM2 antibodies in the corresponding tissue sections. Additionally, a digital image analysis assay was implemented for objectively measuring TP53/MDM2 immunostaining intensity levels.

Results

TP53 protein overexpression was detected in 27/40 (67.5%), whereas MDM2 overexpression in 28/40 (70%) cases. Interestingly, in 21/40 (52.5%) cases, a combined TP53/MDM2 co-expression was detected, whereas in 6/40 (15%), a combined loss of expression was identified (overall co-expression: p=0.119). p53 overexpression was significantly correlated to grade of the examined cases (p=0.001), whereas MDM2 to stage and max diameter of the malignancies (p=0.001 and 0.024, respectively).

Conclusion

TP53/MDM2 over expression is a frequent and significant genetic event in CRCs associated with an aggressive biological behavior, as a result of increased dedifferentiation grade and advanced stage/elevated tumor volume, respectively. MDM2 oncogene overactivation combined with mutated and overexpressed TP53 is observed in sub-groups of patients leading to specific gene/protein signatures – targets for personalized chemotherapeutic approaches.

Keywords: Colon, carcinoma, gene, TP53, MDM2, oncogene, tumor suppressor

Normal cellular microenvironment homeostasis is mediated by critical molecules (1). Among them, tumor protein 53 (TP53) is a leading regulator that enhances the normal genomic function and structural stability (2). The corresponding gene is located on the short (p) arm of chromosome 17 (gene locus: 17p13.1). TP53 gene encodes for a nuclear phosphoprotein (molecular mass of 53 kDa) acting as a central transcription factor. TP53 can enhance apoptotic cell death, also reducing cell proliferation (3). Concerning its activity, it regulates the cell cycle by providing phase arrest at the level of G1/S and G2/M checkpoints (4). Interestingly, the P53/P21/DREAM/ E2F/CHR pathway is involved in cell cycle as a result of P53-mediated indirect transcriptional repression (5). This mechanism prevents DNA damage during DNA replication in the S phase. Additionally, TP53 promotes histone de-acetylation, proteolysis, apoptotic death, and negatively regulates helicase and telomerase activity (6-8). Furthermore, TP53 acts as a strong gene transcription factor, and is involved in critical molecular pathways that provide responses to intracellular hypoxia, modify protein oligomerization, base-excision repair, glucose deficit, apoptosis regulation and mitochondrial DNA stability (9,10).

TP53 interacts with mouse double minute 2 homolog (MDM2). The last molecule (also known as E3 ubiquitin-protein ligase), is referred as a proto-oncogene (gene locus: 12q14.3) that is responsible for the production of a nuclear-localized protein (11). The most crucial biochemical function that MDM2 regulates is the zinc ion binding to specific intra-cellular substrates. The molecule also demonstrates a ligase/transferase (12). MDM2 and TP53 form an auto-regulatory pathway. MDM2 binds directly to TP53, negatively modifying its transcriptional activity, promoting TP53 proteasomal degradation (13). More specifically, MDM2 binds to the TP53 N terminus inducing its ubiquitination and its permanent degradation. MDM2 oncogenic activity is mediated predominantly by gene amplification. In solid malignancies, -prominently in sarcomas and especially in liposarcomas- MDM2 overactivation is frequently correlated to a more aggressive phenotype in subsets of patients with specific genetic signatures (14). MDM2 mutations impair the ability to degrade the TP53 oncoprotein efficiently (15,16). In the current research study, we co-analyzed TP53 and MDM2 proteins in a series of colorectal adenocarcinomas (CRCs), exploring the potential impact of their co-expression levels on clinical-pathological features of the corresponding malignant tissues.

Materials and Methods

Study group and tissue specimens. A series of forty (n=40) archival, formalin-fixed, and paraffin-embedded CRC tissue specimens were obtained covering a broad spectrum of grades of differentiation and stages. Concerning the corresponding patients, nineteen (n=19, 47.5%) were female (mean age=64.5 years), whereas the rest (21, 52.5%) were males (mean age=67.2 years). The whole lab procedure took place in the First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens. The Medical School, National and Kapodistrian University of Athens, Athens, Greece ethics committee consented [Reference ID Research Protocol: 219/13-12-2019 (Research ID: 1920012595-11/12/19] to the use of these tissues stored in coded form in the laboratory of Pathological Anatomy for research purposes, according to World Medical Association Declaration of Helsinki guidelines (2008, revised in 2014). The selected tissues were initially fixed in 10% neutral-buffered formalin. Hematoxylin and eosin (H&E)-stained slides of the corresponding samples were reviewed by two independent pathologists for the final histopathological diagnosis confirmation and classified according to the histological typing and grading criteria of the World Health Organization (WHO) (17).

Immunohistochemistry assay (IHC). Ready-to-use anti-p53 (clone DO7, Dako, Glostrup, Denmark; dilution at 1:40) and anti-MDM2 (clone IF2, Novocastra, Newcastle, UK; dilution at 1:40) mouse monoclonal antibodies were used in the examined tissues. IHC protocols -based on the selected antibodies- were carried out on 4μm tissue sections. The slides were initially deparaffinized in xylene and rehydrated in graded ethanol solutions. Following this stage, the slides were immunostained for the markers based on the EN Vision+ (Dako) protocol by using an automated staining system (I 6000; Biogenex, Fremont, CA, USA) This specific assay is based on a soluble, dextran-polymer system that avoids an endogenous biotin reaction.

Following peroxidase blocking, the tissue sections were incubated by applying the primary antibody for 35 min at room temperature. After this stage, incubation with horseradish peroxidise-labelled polymer-HRP (Dako) LP for 30 min was performed. The antigen-antibody binding was visualized by applying the 3-3, diaminobenzidine tetrahydrochloride (DAB) chromogen (Dako). At the final phase of the IHC process, the tissue sections were slightly counterstained by hematoxylin for 30 secs, dehydrated and mounted. Normal colon tissues expressing the markers were used as positive controls. For negative controls, the primary antibody was omitted. According to the antibody manufacturers, a predominantly nuclear and peri-nuclear staining pattern was considered an acceptable expression pattern for both (Figure 1a).

Figure 1. Digital image analysis (DIA) of a TP53 overexpression colorectal cancer (CRC) case. (a) TP53 strong nuclear staining pattern (400×). (b) Red- painted areas are the substrate for the staining intensity level measurements inside the nuclear microenvironment. (c) Green encircled areas have been measured automatically. The extracted value of 112.70 (in the 0-225 RGB continuous grey scale spectrum of staining intensity) is the result of the objective estimation of TP53 expression. Concerning the DIA protocol, immunostaining intensity values decreasing to 0 represent a progressive overexpression of the marker, whereas values increasing to 255 show a progressive loss of its staining intensity.

Figure 1

Open in a new tab

Digital image analysis assay (DIA). In order for TP53/MDM2 protein expression levels to be quantitatively and objectively evaluated, we implemented a DIA assay using a semi-automated system (hardware: Microscope CX-31, Olympus; Digital camera, Sony, Tokyo, Japan; Windows XP/NIS-Elements Software AR v3.0, Nikon Corp, Tokyo, Japan). The corresponding digital algorithm precisely calculated the corresponding staining intensity levels (densitometry evaluation) in the examined malignant cells. Ten (n=10) areas of interest per tissue section were identified (five high-power optical fields at ×400 magnification) and filed in a digital database as colored snapshots. Measurements were performed by implementing a specific macro (nuclear expression for malignant cells). Normal tissue sections (control) were measured independently and compared to the corresponding values that were extracted from the malignant tissue sections. A broad spectrum of continuous grey scale values (0-255) at the RedGreenBlue (RGB) pattern was available for discriminating different protein expression levels (Figure 1b, c). According to the DIA software, the staining intensity values that progressively decrease to 0 represent a continuous overexpression of the protein. In contrast, staining values that increase to 255 reflect a progressive loss of its staining intensity.

Statistical analysis. The statistics software package IBM SPSS v25 (Armonk, NY, USA) was used. Quantitative variables were presented as mean±standard deviation, while the qualitative variables were presented in frequency tables. To evaluate the relationship between qualitative and quantitative variables, due to the small number of subjects in each group, the nonparametric Mann-Whitney and Kruskal-Wallis tests were applied. To evaluate the relationship between independent qualitative variables, where appropriate, the chi-square (x2) and Fisher exact tests were applied. Statistical significance (p) was evaluated in pairs and differences <0.05 were considered statistically significant.

Results

IHC results and statistical differences (p-Values) are presented in Table I. According to the DIA protein expression analysis, the examined colon adenocarcinoma tissues demonstrated different expression levels. In fact, TP53 protein overexpression (high expression as ≤132 staining intensity values in stained nuclei) was detected in 27/40 (67.5%), whereas MDM2 in 28/40 (70%) cases. In contrast, moderate-low expression staining intensity values (>138 ≤161) in stained nuclei were detected in the rest of the examined cases for both markers. Staining intensity values in the range of 133 and 138 were not detected. Interestingly, in 21/40 (52.5%) cases, a synchronous TP53/MDM2 expression was reported, whereas in 6/40 (15%), a progressive loss of their co-expression was detected (overall co-expression: p=0.119). TP53 overexpression was found to be significantly correlated to the grade of the analyzed cases (p=0.001), whereas MDM2 overall expression demonstrated a strong association with stage and max diameter of the malignancies (p=0.001 and 0.024, respectively).

Table I. Clinicopathological parameters and total combined P53/MDM2 protein expression results.

graphic file with name cdp-4-131-i0001.jpg

Open in a new tab

CRC: Colon adenocarcinoma; OE: overexpression (high expression) staining intensity values ≤132 at stained cells; MLE: moderate-low expression staining intensity values >138 ≤161 at stained cells. p-Values in bold type refer to statistically significant correlations (≤0.05).

Discussion

Identification of unique genetic events in solid malignancies is a modern and optimal approach for oncologists to plan and apply targeted chemotherapeutic strategies to patients (18-20). Concerning the TP53/MDM2 auto-regulatory pathway deregulation, it has been implicated on a variety of solid malignancies, including CRC (21,22). It is well known that TP53 nuclear over expression is detected in ~70-90% of solid malignancies characterized by different histo-genetic origins (23,24). Molecular analyses based on TP53 and other genes- including the K-RAS oncogene - have revealed simultaneous mutations that affect these genetic markers in specific populations (25,26). Besides K-RAS/TP53 mutations, multigene mutations in colon carcinoma patients create specific genetic signatures that modify the corresponding response levels to targeted therapeutic regimens (27,28).

In the current research study, we simultaneously analyzed TP53 and MDM2 proteins in a series of colon carcinoma cases, by implementing a protocol based on the combination of IHC and DIA for objectively estimating their protein expression levels. Our analysis revealed a significant co-expression of the examined markers. Concerning their impact on the clinical-pathological features of the malignancy, TP53 over expression was strongly correlated to the grade of the examined cases, whereas MDM2 to stage and max diameter of the malignancies. Concerning the modern oncological approaches, a combination of wild type P53 enhanced function and MDM2 decreased oncogenic activity should be a crucial step for handling subgroups of patients with specific genetic signatures (29,30). Interestingly, specific mutant TP53 variants (p53K120R) are involved in metabolic process in cancer patients, especially modulating glucose metabolism (31,32). Furthermore, TP53 alterations combined with mucin-5 over expression and microsatellite instability (MSI) are involved in colitis-associated colorectal carcinoma, as a result of a progressive chronic inflammation-dysplasia-cancer carcinogenesis process (33,34). Concerning new agents with anti-tumor activity that target TP53 expression, aurora-A - a key G2/M phase regulator kinase – seems to inhibit the TP53 signaling, negatively affecting the response to oxaliplatin-based treatment in CRC patients (35). Similarly, medicinal plants such as ginkgo biflavones could be used as wild type normal p53 enhancers and also MDM2 inhibitors in CRC patients with specific molecular substrates (36). Additionally, a plant substance derived from Ophiopogon japonicus, named cycloastragenol, demonstrates antioxidant, anti-inflammatory, and anti-cancer effects by inducing apoptosis through p53 and c-MYC regulation (37,38).

Moreover, new genetic markers, such as microRNAs (miRs) and upregulated circular RNAs (circRNAs) seem to critically modify the TP53 expression levels in subsets of CRC patients (39). Two study groups reported a positive role of miR-887-3p in CRC by inhibiting cell proliferation and, in parallel, enhancing apoptotic rates due to wild type P53 activation, whereas miR-338-3p negatively affects the resistance rates to 5-fluorouracil (5-FU) in TP53 mutant CRC cases (40,41). Concerning the potential role of TP53 and MDM2 protein expression levels as reliable biomarkers for onset, progression, prognosis and modifiers of the CRC biological behavior, there is a variety of studies that provide positive results, especially correlating TP53 gene mutations with increased metastatic potential (42,43). Interestingly, specific MDM2 genetic signatures, including single nucleotide polymorphisms, seem to be significant for predicting increased susceptibility risk to CRC development compared with the wild-type T allele carriers (44). Additionally, phosphatase and the tensin homolog (PTEN, 10q23) suppressor gene silencing seems to increase MDM2 phosphorylation leading to normal p53 function in an experimental model of colon carcinogenesis (45).

Conclusion

In conclusion, the TP53 tumor suppressor gene apoptotic activity antagonizes the MDM2 oncogenic activity that induces proliferation in neoplastic and malignantly transformed cells. Mutant TP53 over expression combined with MDM2 over activation are frequently observed in CRC cases correlated to an aggressive biological behavior (dedifferentiation, increased tumor dimensions, and advanced stage). Interestingly, TP53 protein accumulation in the nucleus of tumor cells -as a result of TP53 mutations- does not necessarily combine with decreased MDM2 expression. As MDM2 directly binds to p53 and represses its transcriptional activity promoting p53 degradation, its overactivation negatively affects crucial apoptotic p53-based functions. TP53/MDM2 complex deregulation in solid malignancies, and particularly in CRC, is a target and challenge for further investigation and development of targeted anti-MDM2 strategies for an optimal oncological handling of CRC patients at the basis of specific genetic signatures.

Conflicts of Interest

The Authors declare that they have no conflicts of interest.

Authors’ Contributions

AN and ET: Design of the study and article writing; DD, NK, DP, DS and KCK: review and data evaluation as academic advisors; HS, LM, DD, EF and SM: collection and management of references and published data. All Authors read and approved the final article.

References

  • 1.Naser R, Fakhoury I, El-Fouani A, Abi-Habib R, El-Sibai M. Role of the tumor microenvironment in cancer hallmarks and targeted therapy (Review) Int J Oncol. 2023;62(2):23–33. doi: 10.3892/ijo.2022.5471. [DOI] [PubMed] [Google Scholar]
  • 2.Joerger AC, Fersht AR. The p53 pathway: Origins, inactivation in cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85(1):375–404. doi: 10.1146/annurev-biochem-060815-014710. [DOI] [PubMed] [Google Scholar]
  • 3.Purvis JE, Karhohs KW, Mock C, Batchelor E, Loewer A, Lahav G. p53 dynamics control cell fate. Science. 2012;336(6087):1440–1444. doi: 10.1126/science.1218351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Peng BY, Singh AK, Chan CH, Deng YH, Li PY, Su CW, Wu CY, Deng WP. AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway. BMC Cancer. 2023;23(1):1. doi: 10.1186/s12885-022-10466-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25(1):114–132. doi: 10.1038/cdd.2017.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lipsick J. A history of cancer research: Tumor suppressor genes. Cold Spring Harb Perspect Biol. 2020;12(2):a035907. doi: 10.1101/cshperspect.a035907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 2003;11(3):577–590. doi: 10.1016/s1097-2765(03)00050-9. [DOI] [PubMed] [Google Scholar]
  • 8.Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–265. doi: 10.1016/j.ejca.2017.06.023. [DOI] [PubMed] [Google Scholar]
  • 9.Ozaki T, Nakagawara A. Role of p53 in cell death and human cancers. Cancers (Basel) 2011;3(1):994–1013. doi: 10.3390/cancers3010994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Shirangi TR, Zaika A, Moll UM. Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J. 2002;16(3):420–422. doi: 10.1096/fj.01-0617fje. [DOI] [PubMed] [Google Scholar]
  • 11.Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993;13(1):301–306. doi: 10.1128/mcb.13.1.301-306.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lai Z, Ferry KV, Diamond MA, Wee KE, Kim YB, Ma J, Yang T, Benfield PA, Copeland RA, Auger KR. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J Biol Chem. 2001;276(33):31357–31367. doi: 10.1074/jbc.M011517200. [DOI] [PubMed] [Google Scholar]
  • 13.Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, Nakatani Y, Livingston DM. Polyubiquitination of p53 by a Ubiquitin Ligase Activity of p300. Science. 2003;300(5617):342–344. doi: 10.1126/science.1080386. [DOI] [PubMed] [Google Scholar]
  • 14.Traweek RS, Cope BM, Roland CL, Keung EZ, Nassif EF, Erstad DJ. Targeting the MDM2-p53 pathway in dedifferentiated liposarcoma. Front Oncol. 2022;12:1006959. doi: 10.3389/fonc.2022.1006959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Joseph TW, Zaika A, Moll UM. Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J. 2003;17(12):1622–1630. doi: 10.1096/fj.02-0931com. [DOI] [PubMed] [Google Scholar]
  • 16.Yu ZK, Geyer RK, Maki CG. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000;19(51):5892–5897. doi: 10.1038/sj.onc.1203980. [DOI] [PubMed] [Google Scholar]
  • 17.Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, Washington KM, Carneiro F, Cree IA, WHO Classification of Tumours Editorial Board The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182–188. doi: 10.1111/his.13975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Albertson RC, Cresko W, Detrich HW 3rd, Postlethwait JH. Evolutionary mutant models for human disease. Trends Genet. 2009;25(2):74–81. doi: 10.1016/j.tig.2008.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gronroos E, López-García C. Tolerance of chromosomal instability in cancer: Mechanisms and therapeutic opportunities. Cancer Res. 2018;78(23):6529–6535. doi: 10.1158/0008-5472.CAN-18-1958. [DOI] [PubMed] [Google Scholar]
  • 20.Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34(4):369–376. doi: 10.1038/ng1215. [DOI] [PubMed] [Google Scholar]
  • 21.Italiano A. Targeting MDM2 in soft-tissue sarcomas (and other solid tumors): The revival. Cancer Discov. 2023;13(8):1765–1767. doi: 10.1158/2159-8290.CD-23-0605. [DOI] [PubMed] [Google Scholar]
  • 22.Brummer T, Zeiser R. The role of the MDM2/p53 axis in anti-tumor immune responses. Blood. 2023:2023020731. doi: 10.1182/blood.2023020731. [DOI] [PubMed] [Google Scholar]
  • 23.Marques JF, Kops GJPL. Permission to pass: on the role of p53 as a gatekeeper for aneuploidy. Chromosome Res. 2023;31(4):31. doi: 10.1007/s10577-023-09741-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Mansur MB, Greaves M. Convergent TP53 loss and evolvability in cancer. BMC Ecol Evol. 2023;23(1):54. doi: 10.1186/s12862-023-02146-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Afrăsânie VA, Marinca MV, Gafton B, Alexa-Stratulat T, Rusu A, Froicu EM, Sur D, Lungulescu CV, Popovici L, Lefter AV, Afrăsânie I, Ivanov AV, Miron L, Rusu C. Clinical, pathological and molecular insights on KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in metastatic colorectal cancer patients from northeastern Romania. Int J Mol Sci. 2023;24(16):12679. doi: 10.3390/ijms241612679. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Răduţă D, Dincă OM, Micu GV, Nichita L, Cioplea MD, Buşcă RM, Ardeleanu R, Mateescu RB, Benguş A, Zurac SA, Popp CG, Vlădan GC. MLH1, BRAF and p53 – searching for significant markers to predict evolution towards adenocarcinoma in colonic sessile serrated lesions. Rom J Morphol Embryol. 2021;62(4):971–979. doi: 10.47162/RJME.62.4.09. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Shen CJ, Chan RH, Lin BW, Li NC, Huang YH, Chang WC, Chen BK. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation. Theranostics. 2023;13(13):4650–4666. doi: 10.7150/thno.85855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ottaiano A, Santorsola M, Capuozzo M, Perri F, Circelli L, Cascella M, Ianniello M, Sabbatino F, Granata V, Izzo F, Iervolino D, Casillo M, Petrillo N, Gualillo O, Nasti G, Savarese G. The prognostic role of p53 mutations in metastatic colorectal cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;186:104018. doi: 10.1016/j.critrevonc.2023.104018. [DOI] [PubMed] [Google Scholar]
  • 29.Dey DK, Sharma C, Vadlamudi Y, Kang SC. CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery. Life Sci. 2023;318:121476. doi: 10.1016/j.lfs.2023.121476. [DOI] [PubMed] [Google Scholar]
  • 30.Hadni H, Elhallaoui M. Discovery of anti-colon cancer agents targeting wild-type and mutant p53 using computer-aided drug design. J Biomol Struct Dyn. 2023;41(19):10171–10189. doi: 10.1080/07391102.2022.2153919. [DOI] [PubMed] [Google Scholar]
  • 31.Monti P, Ravera S, Speciale A, Velkova I, Foggetti G, Degan P, Fronza G, Menichini P. Mutant p53(K120R) expression enables a partial capacity to modulate metabolism. Front Genet. 2022;13:974662. doi: 10.3389/fgene.2022.974662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Tang M, Xu H, Huang H, Kuang H, Wang C, Li Q, Zhang X, Ge Y, Song M, Zhang X, Wang Z, Ma C, Kang J, Zhang W, Wang Y, Zhang B, Zhang X, Chen Y, Cong M, Melino G, Wang X, Zhou F, Sun Q, Shi H. Metabolism-based molecular subtyping endows effective ketogenic therapy in p53-mutant colon cancer. Adv Sci (Weinh) 2022;9(29):e2201992. doi: 10.1002/advs.202201992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Gené M, Cuatrecasas M, Amat I, Veiga JA, Fernández Aceñero MJ, Fusté Chimisana V, Tarragona J, Jurado I, Fernández-Victoria R, Martínez Ciarpaglini C, Alenda González C, Zac C, Ortega de la Obra P, Fernández-Figueras MT, Esteller M, Musulen E. Alterations in p53, microsatellite stability and lack of MUC5AC expression as molecular features of colorectal carcinoma associated with inflammatory bowel disease. Int J Mol Sci. 2023;24(10):8655. doi: 10.3390/ijms24108655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Foersch S, Neurath MF. Colitis-associated neoplasia: molecular basis and clinical translation. Cell Mol Life Sci. 2014;71(18):3523–3535. doi: 10.1007/s00018-014-1636-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chen MC, Yang BZ, Kuo WW, Wu SH, Wang TF, Yeh YL, Chen MC, Huang CY. The involvement of Aurora-A and p53 in oxaliplatin-resistant colon cancer cells. J Cell Biochem. 2023;124(4):619–632. doi: 10.1002/jcb.30394. [DOI] [PubMed] [Google Scholar]
  • 36.Zhang S, Sun Y, Yao F, Li H, Yang Y, Li X, Bai Z, Hu Y, Wang P, Xu X. Ginkgo biflavones cause p53 wild-type dependent cell death in a transcription-independent manner of p53. J Nat Prod. 2023;86(2):346–356. doi: 10.1021/acs.jnatprod.2c00959. [DOI] [PubMed] [Google Scholar]
  • 37.Ko HM, Jee W, Lee D, Jang HJ, Jung JH. Ophiopogonin D increase apoptosis by activating p53 via ribosomal protein L5 and L11 and inhibiting the expression of c-Myc via CNOT2. Front Pharmacol. 2022;13:974468. doi: 10.3389/fphar.2022.974468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Park D, Jung JH, Ko HM, Jee W, Kim H, Jang HJ. Antitumor effect of cycloastragenol in colon cancer cells via p53 activation. Int J Mol Sci. 2022;23(23):15213. doi: 10.3390/ijms232315213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Weidle UH, Nopora A. Up-regulated circular RNAs in colorectal cancer: New entities for therapy and tools for identification of therapeutic targets. Cancer Genomics Proteomics. 2023;20(2):132–153. doi: 10.21873/cgp.20369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Teng D, Xia S, Hu S, Yan Y, Liu B, Yang Y, Du X. miR-887-3p inhibits the progression of colorectal cancer via downregulating DNMT1 expression and regulating P53 expression. Comput Intell Neurosci. 2022;2022:7179733. doi: 10.1155/2022/7179733. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 41.Han J, Li J, Tang K, Zhang H, Guo B, Hou N, Huang C. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin. Exp Cell Res. 2017;360(2):328–336. doi: 10.1016/j.yexcr.2017.09.023. [DOI] [PubMed] [Google Scholar]
  • 42.Hirabayashi S, Hayashi M, Nakayama G, Mii S, Hattori N, Tanabe H, Kanda M, Tanaka C, Kobayashi D, Yamada S, Koike M, Fujiwara M, Takahashi M, Kodera Y. The significance of molecular biomarkers on clinical survival outcome differs depending on colon cancer sidedness. Anticancer Res. 2020;40(1):201–211. doi: 10.21873/anticanres.13941. [DOI] [PubMed] [Google Scholar]
  • 43.Lee JH, Ahn BK, Baik SS, Lee KH. Comprehensive analysis of somatic mutations in colorectal cancer with peritoneal metastasis. In Vivo. 2019;33(2):447–452. doi: 10.21873/invivo.11493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Yueh TC, Hung YW, Shih TC, Wu CN, Wang SC, Lai YL, Hsu SW, Wu MH, Fu CK, Wang YC, Ke TW, Chang WS, Tsai CW, Bau DT. Contribution of murine double minute 2 genotypes to colorectal cancer risk in Taiwan. Cancer Genomics Proteomics. 2018;15(5):405–411. doi: 10.21873/cgp.20099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ren G, Yang EJ, Tao S, Mou PK, Pu Y, Chen LJ, Shim JS. MDM2 inhibition is synthetic lethal with PTEN loss in colorectal cancer cells via the p53-dependent mechanism. Int J Biol Sci. 2023;19(11):3544–3557. doi: 10.7150/ijbs.82566. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Diagnosis & Prognosis are provided here courtesy of International Institute of Anticancer Research

RESOURCES